INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2006

Curcumin reduced relapse rates and improved clinical measures in quiescent ulcerative colitis.

In a randomized trial of 89 participants with quiescent ulcerative colitis, participants received 2 g daily of curcumin or placebo alongside standard therapy for 6 months. Among per-protocol participants, 4.65% (2 of 43) in the curcumin group relapsed compared to 20.51% (8 of 39) in the placebo group (P = 0.040; intention-to-treat P = 0.049). Curcumin also significantly improved both the clinical activity index (P = 0.038) and the endoscopic index (P = 0.0001).

Study type
Randomized controlled trial
Who was studied
89 patients with quiescent ulcerative colitis
What was measured
Relapse rate and endoscopic/clinical indices at 6 months

THE PAPER

Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Clin Gastroenterol Hepatol, 2006.

PubMed 17101300 ↗DOI 10.1016/j.cgh.2006.08.008 ↗

Gut & microbiome

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.